ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $545.83 ($539.12–$557.04, $5.19M total) across 17 trades on 2026-06-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor whether insider selling accelerates beyond planned schedules, but this specific disclosure is explicitly pre-arranged under Rule 10b5-1.
Market read
A $5.19M CEO/Chair sale under a 10b5-1 plan is a measurable insider activity datapoint, but typically not a strong standalone fundamental catalyst.
What to watch
The article doesn’t state whether the insider’s remaining holdings changed materially beyond the post-sale share count, nor does it provide context on prior 10b5-1 schedules or total planned volume.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
SEC Form 4 shows UTHR CEO/Chair Martine Rothblatt sold $5.19M of United Therapeutics shares via an open-market sale under a 10b5-1 plan.
Likely limited immediate price impact; any effect is more sentiment/positioning than fundamentals.
The filing is a primary-source insider transaction with defined sale size and timing, but it is explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretive strength versus unscheduled sales.
Market effects
No direct sector read-through; this is company-specific insider liquidity/portfolio management information.
None indicated.
None indicated.
Counterpoint
Because the sales were executed under a 10b5-1 plan, the market may overreact; the disclosure may not reflect new negative information about UTHR fundamentals.
Key entities
- issuerUnited Therapeutics Corp
Company whose shares were sold by an insider (CEO/Chair Martine Rothblatt).
- insiderMartine A. Rothblatt
Chairperson & CEO who sold 9,500 shares in open-market transactions under a 10b5-1 plan.
